Inhibition of STAT3 in gastric cancer: role of pantoprazole as SHP-1 inducer

[1]  Hongwei Wang,et al.  Luteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1 , 2017, Cell Death & Disease.

[2]  Lihong Yang,et al.  Proton pump inhibitor pantoprazole inhibits the proliferation, self‑renewal and chemoresistance of gastric cancer stem cells via the EMT/β‑catenin pathways. , 2016, Oncology reports.

[3]  A. Kaneda,et al.  Host SHP1 phosphatase antagonizes Helicobacter pylori CagA and can be downregulated by Epstein–Barr virus , 2016, Nature Microbiology.

[4]  S. Hahn,et al.  Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. , 2016, The Lancet. Oncology.

[5]  C. Burns,et al.  Targeting JAK kinase in solid tumors: emerging opportunities and challenges , 2016, Oncogene.

[6]  Xin Li,et al.  Prognostic Value and Clinicopathological Significance of p-stat3 Among Gastric Carcinoma Patients , 2016, Medicine.

[7]  H. Chun,et al.  Epigenetic regulation and anti-tumorigenic effects of SH2-containing protein tyrosine phosphatase 1 (SHP1) in human gastric cancer cells , 2016, Tumor Biology.

[8]  Z. Shao,et al.  Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer , 2015, Journal of Experimental & Clinical Cancer Research.

[9]  A. Cheng,et al.  Proton pump inhibitor pantoprazole abrogates adriamycin-resistant gastric cancer cell invasiveness via suppression of Akt/GSK-β/β-catenin signaling and epithelial-mesenchymal transition. , 2015, Cancer letters.

[10]  D. Forman,et al.  The fight against gastric cancer - the IARC Working Group report. , 2014, Best practice & research. Clinical gastroenterology.

[11]  B. Bonavida,et al.  Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention , 2014, Journal of experimental & clinical cancer research : CR.

[12]  Jie Xu,et al.  TMEFF2 Deregulation Contributes to Gastric Carcinogenesis and Indicates Poor Survival Outcome , 2014, Clinical Cancer Research.

[13]  J. Imura,et al.  IL-22 produced by cancer-associated fibroblasts promotes gastric cancer cell invasion via STAT3 and ERK signaling , 2014, British Journal of Cancer.

[14]  H. Ling,et al.  Inhibition of the JAK2/STAT3 Pathway Reduces Gastric Cancer Growth In Vitro and In Vivo , 2014, PloS one.

[15]  G. Sethi,et al.  Capillarisin inhibits constitutive and inducible STAT3 activation through induction of SHP-1 and SHP-2 tyrosine phosphatases. , 2014, Cancer letters.

[16]  D. Huszar,et al.  Therapeutic Inhibition of Jak Activity Inhibits Progression of Gastrointestinal Tumors in Mice , 2014, Molecular Cancer Therapeutics.

[17]  X. Zou,et al.  Proton pump inhibitor selectively suppresses proliferation and restores the chemosensitivity of gastric cancer cells by inhibiting STAT3 signaling pathway. , 2013, International immunopharmacology.

[18]  Y. Bang,et al.  OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. , 2013, Cancer letters.

[19]  M. Sitbon,et al.  Optimization of tumor xenograft dissociation for the profiling of cell surface markers and nutrient transporters , 2013, Laboratory Investigation.

[20]  K. Lan,et al.  Calpain/SHP-1 Interaction by Honokiol Dampening Peritoneal Dissemination of Gastric Cancer in nu/nu Mice , 2012, PloS one.

[21]  A. Giraud,et al.  Targeting STAT3 in gastric cancer , 2012, Expert opinion on therapeutic targets.

[22]  J. Nam,et al.  Responsive nematic gels from the self-assembly of aqueous nanofibres. , 2011, Nature communications.

[23]  M. Garcia-Marcos,et al.  Src Homology Domain 2-containing Protein-tyrosine Phosphatase-1 (SHP-1) Binds and Dephosphorylates Gα-interacting, Vesicle-associated Protein (GIV)/Girdin and Attenuates the GIV-Phosphatidylinositol 3-Kinase (PI3K)-Akt Signaling Pathway* , 2011, The Journal of Biological Chemistry.

[24]  X. Bian,et al.  HOXB7 as a Prognostic Factor and Mediator of Colorectal Cancer Progression , 2011, Clinical Cancer Research.

[25]  J. Rodríguez-Ubreva,et al.  SHP-1 in cell-cycle regulation. , 2011, Anti-cancer agents in medicinal chemistry.

[26]  B. Aggarwal,et al.  Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP‐1 in human multiple myeloma cells , 2010, International journal of cancer.

[27]  Guoqiang Chen,et al.  Inhibition of DNA methyltransferase induces G2 cell cycle arrest and apoptosis in human colorectal cancer cells via inhibition of JAK2/STAT3/STAT5 signalling , 2009, Journal of cellular and molecular medicine.

[28]  P. Yue,et al.  Targeting STAT3 in cancer: how successful are we? , 2009, Expert opinion on investigational drugs.

[29]  Carlos Barrientos,et al.  Reprimo as a Potential Biomarker for Early Detection in Gastric Cancer , 2008, Clinical Cancer Research.

[30]  H. Itoh,et al.  Expression of HSP72 in the gastric mucosa is regulated by gastric acid in rats-correlation of HSP72 expression with mucosal protection. , 2006, Biochemical and biophysical research communications.

[31]  K. Hahm,et al.  Selective Induction of Apoptosis with Proton Pump Inhibitor in Gastric Cancer Cells , 2004, Clinical Cancer Research.

[32]  K. Hayashi,et al.  Activated Proliferation of B-Cell Lymphomas/Leukemias with the SHP1 Gene Silencing by Aberrant CpG Methylation , 2003, Laboratory Investigation.

[33]  Lijun Liu,et al.  The function of the protein tyrosine phosphatase SHP-1 in cancer. , 2003, Gene.

[34]  L. Buscail,et al.  Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1. , 2002, The Journal of clinical endocrinology and metabolism.

[35]  R. Blamey,et al.  Up‐regulation of the protein tyrosine phosphatase SHP‐1 in human breast cancer and correlation with GRB2 expression , 2000, International journal of cancer.